Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients

BACKGROUND: The validation of KRAS mutations as a negative marker of response to anti-epidermal growth factor receptor (EGFR) antibodies has meant a seminal advance towards treatment individualisation of colorectal cancer (CRC) patients. However, as a KRAS wild-type status does not guarantee a respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Montagut, C, Iglesias, M, Arumi, M, Bellosillo, B, Gallen, M, Martinez-Fernandez, A, Martinez-Aviles, L, Cañadas, I, Dalmases, A, Moragon, E, Lema, L, Serrano, S, Rovira, A, Rojo, F, Bellmunt, J, Albanell, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2853100/
https://www.ncbi.nlm.nih.gov/pubmed/20234366
http://dx.doi.org/10.1038/sj.bjc.6605612

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2853100/
https://www.ncbi.nlm.nih.gov/pubmed/20234366
http://dx.doi.org/10.1038/sj.bjc.6605612

Ejemplares similares